Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 39 entries
Sorted by: Best Match Show Resources per page
Drug discovery: a modern decathlon.

Angewandte Chemie (International ed. in English)

Laufer S, Holzgrabe U, Steinhilber D.
PMID: 23468378
Angew Chem Int Ed Engl. 2013 Apr 08;52(15):4072-6. doi: 10.1002/anie.201210006. Epub 2013 Mar 06.

No abstract available.

Cite
Laufer S, Holzgrabe U, Steinhilber D. Drug discovery: a modern decathlon. Angew Chem Int Ed Engl. 2013;52(15):4072-6doi: 10.1002/anie.201210006.
Laufer, S., Holzgrabe, U., & Steinhilber, D. (2013). Drug discovery: a modern decathlon. Angewandte Chemie (International ed. in English), 52(15), 4072-6. https://doi.org/10.1002/anie.201210006
Laufer, Stefan, et al. "Drug discovery: a modern decathlon." Angewandte Chemie (International ed. in English) vol. 52,15 (2013): 4072-6. doi: https://doi.org/10.1002/anie.201210006
Laufer S, Holzgrabe U, Steinhilber D. Drug discovery: a modern decathlon. Angew Chem Int Ed Engl. 2013 Apr 08;52(15):4072-6. doi: 10.1002/anie.201210006. Epub 2013 Mar 06. PMID: 23468378.
Copy Download .nbib Format: NLM
Price indices of drugs and the switching to new drugs. Two empirical examples.

PharmacoEconomics

Gerdtham UG, Gunnarsson B, Henriksson F, Johannesson M, Marcusson M.
PMID: 10175987
Pharmacoeconomics. 1998 Jan;13(1):71-80. doi: 10.2165/00019053-199813010-00007.

Standard price indices may not account for the price decrease that results when patients switch to pharmaceutical products for which their demand-reservation price exceeds the price of the new product. In a similar way, standard price indices may not...

Cite
Gerdtham UG, Gunnarsson B, Henriksson F, et al. Price indices of drugs and the switching to new drugs. Two empirical examples. Pharmacoeconomics. 1998;13(1):71-80doi: 10.2165/00019053-199813010-00007.
Gerdtham, U. G., Gunnarsson, B., Henriksson, F., Johannesson, M., & Marcusson, M. (1998). Price indices of drugs and the switching to new drugs. Two empirical examples. PharmacoEconomics, 13(1), 71-80. https://doi.org/10.2165/00019053-199813010-00007
Gerdtham, U G, et al. "Price indices of drugs and the switching to new drugs. Two empirical examples." PharmacoEconomics vol. 13,1 (1998): 71-80. doi: https://doi.org/10.2165/00019053-199813010-00007
Gerdtham UG, Gunnarsson B, Henriksson F, Johannesson M, Marcusson M. Price indices of drugs and the switching to new drugs. Two empirical examples. Pharmacoeconomics. 1998 Jan;13(1):71-80. doi: 10.2165/00019053-199813010-00007. PMID: 10175987.
Copy Download .nbib Format: NLM
Quantitative Structure-Price Relationship (QS$R) Modeling and the Development of Economically Feasible Drug Discovery Projects.

Journal of chemical information and modeling

Fernandez M, Ban F, Woo G, Isaev O, Perez C, Fokin V, Tropsha A, Cherkasov A.
PMID: 30767528
J Chem Inf Model. 2019 Apr 22;59(4):1306-1313. doi: 10.1021/acs.jcim.8b00747. Epub 2019 Feb 28.

In recent years, the field of quantitative structure-activity/property relationship (QSAR/QSPR) modeling has developed into a stable technology capable of reliably predicting new bioactive molecules. With the availability of inexpensive commercial sources of both synthetic chemicals and bioactivity assays, a...

Cite
Fernandez M, Ban F, Woo G, et al. Quantitative Structure-Price Relationship (QS$R) Modeling and the Development of Economically Feasible Drug Discovery Projects. J Chem Inf Model. 2019;59(4):1306-1313doi: 10.1021/acs.jcim.8b00747.
Fernandez, M., Ban, F., Woo, G., Isaev, O., Perez, C., Fokin, V., Tropsha, A., & Cherkasov, A. (2019). Quantitative Structure-Price Relationship (QS$R) Modeling and the Development of Economically Feasible Drug Discovery Projects. Journal of chemical information and modeling, 59(4), 1306-1313. https://doi.org/10.1021/acs.jcim.8b00747
Fernandez, Michael, et al. "Quantitative Structure-Price Relationship (QS$R) Modeling and the Development of Economically Feasible Drug Discovery Projects." Journal of chemical information and modeling vol. 59,4 (2019): 1306-1313. doi: https://doi.org/10.1021/acs.jcim.8b00747
Fernandez M, Ban F, Woo G, Isaev O, Perez C, Fokin V, Tropsha A, Cherkasov A. Quantitative Structure-Price Relationship (QS$R) Modeling and the Development of Economically Feasible Drug Discovery Projects. J Chem Inf Model. 2019 Apr 22;59(4):1306-1313. doi: 10.1021/acs.jcim.8b00747. Epub 2019 Feb 28. PMID: 30767528.
Copy Download .nbib Format: NLM
A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors.

Health policy and planning

Schram A, Ruckert A, VanDuzer JA, Friel S, Gleeson D, Thow AM, Stuckler D, Labonte R.
PMID: 29106574
Health Policy Plan. 2018 Jan 01;33(1):123-136. doi: 10.1093/heapol/czx133.

We developed a conceptual framework exploring pathways between trade and investment and noncommunicable disease (NCD) outcomes. Despite increased knowledge of the relevance of social and structural determinants of health, the discourse on NCD prevention has been dominated by individualizing...

Cite
Schram A, Ruckert A, VanDuzer JA, et al. A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors. Health Policy Plan. 2018;33(1):123-136doi: 10.1093/heapol/czx133.
Schram, A., Ruckert, A., VanDuzer, J. A., Friel, S., Gleeson, D., Thow, A. M., Stuckler, D., & Labonte, R. (2018). A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors. Health policy and planning, 33(1), 123-136. https://doi.org/10.1093/heapol/czx133
Schram, Ashley, et al. "A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors." Health policy and planning vol. 33,1 (2018): 123-136. doi: https://doi.org/10.1093/heapol/czx133
Schram A, Ruckert A, VanDuzer JA, Friel S, Gleeson D, Thow AM, Stuckler D, Labonte R. A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors. Health Policy Plan. 2018 Jan 01;33(1):123-136. doi: 10.1093/heapol/czx133. PMID: 29106574; PMCID: PMC5886114.
Copy Download .nbib Format: NLM
Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches.

Current medical research and opinion

Broder MS, Zambrano JM, Lee J, Marken RS.
PMID: 28418263
Curr Med Res Opin. 2018 May;34(5):765-773. doi: 10.1080/03007995.2017.1320276. Epub 2017 May 03.

OBJECTIVE: Expectations about the budget impact of new drug launches may affect payer behavior and ultimately consumer costs. Therefore, we evaluated the accuracy of pre-launch US budget impact estimates for a sample of new drugs.METHODS: We searched for publicly...

Cite
Broder MS, Zambrano JM, Lee J, et al. Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. Curr Med Res Opin. 2017;34(5):765-773doi: 10.1080/03007995.2017.1320276.
Broder, M. S., Zambrano, J. M., Lee, J., & Marken, R. S. (2018). Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. Current medical research and opinion, 34(5), 765-773. https://doi.org/10.1080/03007995.2017.1320276
Broder, Michael S, et al. "Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches." Current medical research and opinion vol. 34,5 (2018): 765-773. doi: https://doi.org/10.1080/03007995.2017.1320276
Broder MS, Zambrano JM, Lee J, Marken RS. Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. Curr Med Res Opin. 2018 May;34(5):765-773. doi: 10.1080/03007995.2017.1320276. Epub 2017 May 03. PMID: 28418263.
Copy Download .nbib Format: NLM
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?.

PharmacoEconomics

Mestre-Ferrandiz J, Zozaya N, Alcalá B, Hidalgo-Vega Á.
PMID: 30198061
Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4.

For medicines with different valued indications (uses), multi-indication pricing implies charging different prices for different uses. In this article, we assess how multi-indication pricing could help achieve overall strategic objectives of pricing controls, summarise its advantages and disadvantages (vs....

Cite
Mestre-Ferrandiz J, Zozaya N, Alcalá B, et al. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. Pharmacoeconomics. 2018;36(12):1407-1420doi: 10.1007/s40273-018-0716-4.
Mestre-Ferrandiz, J., Zozaya, N., Alcalá, B., & Hidalgo-Vega, �. �. (2018). Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. PharmacoEconomics, 36(12), 1407-1420. https://doi.org/10.1007/s40273-018-0716-4
Mestre-Ferrandiz, Jorge, et al. "Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?." PharmacoEconomics vol. 36,12 (2018): 1407-1420. doi: https://doi.org/10.1007/s40273-018-0716-4
Mestre-Ferrandiz J, Zozaya N, Alcalá B, Hidalgo-Vega Á. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?. Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4. PMID: 30198061.
Copy Download .nbib Format: NLM
Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?.

Tropical doctor

Meher BR, Padhy BM.
PMID: 32036770
Trop Doct. 2020 Apr;50(2):157-159. doi: 10.1177/0049475520903644. Epub 2020 Feb 09.

The concept of indication-specific pricing (ISP) of drugs means that the cost of a drug will vary depending on the reasons for its use. ISP is a novel concept and its beneficial or detrimental effects are unknown. Experience from...

Cite
Meher BR, Padhy BM. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Trop Doct. 2020;50(2):157-159doi: 10.1177/0049475520903644.
Meher, B. R., & Padhy, B. M. (2020). Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Tropical doctor, 50(2), 157-159. https://doi.org/10.1177/0049475520903644
Meher, Bikash R, and Padhy, Biswa M. "Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?." Tropical doctor vol. 50,2 (2020): 157-159. doi: https://doi.org/10.1177/0049475520903644
Meher BR, Padhy BM. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?. Trop Doct. 2020 Apr;50(2):157-159. doi: 10.1177/0049475520903644. Epub 2020 Feb 09. PMID: 32036770.
Copy Download .nbib Format: NLM
New drugs: who can afford them?.

Cadernos de saude publica

Bermudez JA, Oliveira MA, Chaves GC.
PMID: 27828670
Cad Saude Publica. 2016 Nov 03;32:e00025215. doi: 10.1590/0102-311X00025215.

No abstract available.

Cite
Bermudez JA, Oliveira MA, Chaves GC. New drugs: who can afford them?. Cad Saude Publica. 2016;32:e00025215doi: 10.1590/0102-311X00025215.
Bermudez, J. A., Oliveira, M. A., & Chaves, G. C. (2016). New drugs: who can afford them?. Cadernos de saude publica, 32e00025215. https://doi.org/10.1590/0102-311X00025215
Bermudez, Jorge Antonio Zepeda, et al. "New drugs: who can afford them?." Cadernos de saude publica vol. 32 (2016): e00025215. doi: https://doi.org/10.1590/0102-311X00025215
Bermudez JA, Oliveira MA, Chaves GC. New drugs: who can afford them?. Cad Saude Publica. 2016 Nov 03;32:e00025215. doi: 10.1590/0102-311X00025215. Portuguese. PMID: 27828670.
Copy Download .nbib Format: NLM
Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.

Journal of managed care & specialty pharmacy

Yu JS, Chin L, Oh J, Farias J.
PMID: 28944733
J Manag Care Spec Pharm. 2017 Oct;23(10):1028-1040. doi: 10.18553/jmcp.2017.23.10.1028.

BACKGROUND: Value for money is a growing necessity in today's U.S. health care system in which drug spending is expected to increase by an average rate of 6.7% yearly through 2025. In response to uncertainty about real-world clinical and...

Cite
Yu JS, Chin L, Oh J, et al. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review. J Manag Care Spec Pharm. 2017;23(10):1028-1040doi: 10.18553/jmcp.2017.23.10.1028.
Yu, J. S., Chin, L., Oh, J., & Farias, J. (2017). Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review. Journal of managed care & specialty pharmacy, 23(10), 1028-1040. https://doi.org/10.18553/jmcp.2017.23.10.1028
Yu, Justin S, et al. "Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review." Journal of managed care & specialty pharmacy vol. 23,10 (2017): 1028-1040. doi: https://doi.org/10.18553/jmcp.2017.23.10.1028
Yu JS, Chin L, Oh J, Farias J. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review. J Manag Care Spec Pharm. 2017 Oct;23(10):1028-1040. doi: 10.18553/jmcp.2017.23.10.1028. PMID: 28944733.
Copy Download .nbib Format: NLM
Analysis of Scientific Research Driving Microalgae Market Opportunities in Europe.

Marine drugs

Rumin J, Nicolau E, Junior RGO, Fuentes-Grünewald C, Picot L.
PMID: 32443631
Mar Drugs. 2020 May 18;18(5). doi: 10.3390/md18050264.

A bibliographic database of scientific papers published by authors affiliated to research institutions worldwide, especially focused in Europe and in the European Atlantic Area, and containing the keywords "microalga(e)" or "phytoplankton" was built. A corpus of 79,020 publications was...

Cite
Rumin J, Nicolau E, Junior RGO, et al. Analysis of Scientific Research Driving Microalgae Market Opportunities in Europe. Mar Drugs. 2020;18(5)doi: 10.3390/md18050264.
Rumin, J., Nicolau, E., Junior, R. G. O., Fuentes-Grünewald, C., & Picot, L. (2020). Analysis of Scientific Research Driving Microalgae Market Opportunities in Europe. Marine drugs, 18(5), . https://doi.org/10.3390/md18050264
Rumin, Judith, et al. "Analysis of Scientific Research Driving Microalgae Market Opportunities in Europe." Marine drugs vol. 18,5 (2020). doi: https://doi.org/10.3390/md18050264
Rumin J, Nicolau E, Junior RGO, Fuentes-Grünewald C, Picot L. Analysis of Scientific Research Driving Microalgae Market Opportunities in Europe. Mar Drugs. 2020 May 18;18(5). doi: 10.3390/md18050264. PMID: 32443631; PMCID: PMC7281102.
Copy Download .nbib Format: NLM
New drugs and lower costs.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Levy R.
PMID: 12374085
Am J Health Syst Pharm. 2002 Oct 01;59(19):1894; author reply 1895. doi: 10.1093/ajhp/59.19.1894.

No abstract available.

Cite
Levy R. New drugs and lower costs. Am J Health Syst Pharm. 2002;59(19):1894; author reply 1895doi: 10.1093/ajhp/59.19.1894.
Levy, R. (2002). New drugs and lower costs. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 59(19), 1894; author reply 1895. https://doi.org/10.1093/ajhp/59.19.1894
Levy, Richard. "New drugs and lower costs." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 59,19 (2002): 1894; author reply 1895. doi: https://doi.org/10.1093/ajhp/59.19.1894
Levy R. New drugs and lower costs. Am J Health Syst Pharm. 2002 Oct 01;59(19):1894; author reply 1895. doi: 10.1093/ajhp/59.19.1894. PMID: 12374085.
Copy Download .nbib Format: NLM
The NHS drug budget inquiry. A note for the Commons Health Select Committee.

Journal of the Royal College of Physicians of London

Herxheimer A.
PMID: 7932326
J R Coll Physicians Lond. 1994 May-Jun;28(3):261-3.

No abstract available.

Cite
Herxheimer A. The NHS drug budget inquiry. A note for the Commons Health Select Committee. J R Coll Physicians Lond. 1994;28(3):261-3
Herxheimer, A. (1994). The NHS drug budget inquiry. A note for the Commons Health Select Committee. Journal of the Royal College of Physicians of London, 28(3), 261-3.
Herxheimer, A. "The NHS drug budget inquiry. A note for the Commons Health Select Committee." Journal of the Royal College of Physicians of London vol. 28,3 (1994): 261-3.
Herxheimer A. The NHS drug budget inquiry. A note for the Commons Health Select Committee. J R Coll Physicians Lond. 1994 May-Jun;28(3):261-3. PMID: 7932326; PMCID: PMC5400991.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 39 entries